Cost and Cost Effectiveness of Treatments for Psoriatic Arthritis: A Systematic Literature Review View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2018-02-13

AUTHORS

Lucia Sara D’Angiolella, Paolo Angelo Cortesi, Alessandra Lafranconi, Mariangela Micale, Sveva Mangano, Giancarlo Cesana, Lorenzo Giovanni Mantovani

ABSTRACT

BackgroundPsoriatic arthritis is a long-term inflammatory arthropathy occurring in a subgroup of patients with psoriasis. In addition to irreversible bone erosions, joint destruction, and skin manifestations, psoriatic arthritis is associated with numerous comorbid conditions. Over the last 5 years, new treatments emerged; the analysis and comparisons of their additional costs and the added benefits have become increasingly important to optimize the limited resources available.MethodsA systematic literature review covering PubMed, EMBASE, and the Cochrane Library was performed from May 2012 to October 2017 focusing on the most recent evidence of costs, benefits, and burden of psoriatic arthritis and its treatments. All economic evaluations assessing the burden of patients with psoriatic arthritis and written in English were eligible for inclusion. We also performed an assessment of the quality of the studies.ResultsOf the 1652 references found in the literature search, nine cost-effectiveness analyses and 12 cost-of-illness studies were included in the current review. Patients with psoriatic arthritis incur substantially higher direct and indirect costs, as compared with patients with psoriasis without arthritis or patients with other inflammatory diseases. The cost of treatment with biologic therapies is the major predictor of the total cost. However, individuals with psoriatic arthritis are also affected by substantial productivity losses and indirect costs. Biologic therapies are generally cost effective vs. conventional therapies (e.g., synthetic drugs) for treating psoriatic arthritis.ConclusionsPsoriatic arthritis is associated with a significant economic burden and biologic therapies contribute significantly to these costs. Biologic therapies are more effective than disease-modifying anti-rheumatic drugs for the symptoms and signs of psoriatic arthritis and for improving quality of life and inhibiting structural radiological damage. Therefore, biologic therapies are cost effective compared with conventional therapies: the increased direct cost associated with biologic drugs is offset by the significant improvement in the efficacy of treatments and in patient management of psoriatic arthritis. More... »

PAGES

567-589

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s40273-018-0618-5

DOI

http://dx.doi.org/10.1007/s40273-018-0618-5

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1101005767

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29441473


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antirheumatic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Arthritis, Psoriatic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cost of Illness", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cost-Benefit Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Costs", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Research Centre on Public Health (CESP), University of Milan-Bicocca, Via G. Pergolesi 33, 20900, Monza, Italy", 
          "id": "http://www.grid.ac/institutes/grid.7563.7", 
          "name": [
            "Research Centre on Public Health (CESP), University of Milan-Bicocca, Via G. Pergolesi 33, 20900, Monza, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "D\u2019Angiolella", 
        "givenName": "Lucia Sara", 
        "id": "sg:person.01223133176.57", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01223133176.57"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Research Centre on Public Health (CESP), University of Milan-Bicocca, Via G. Pergolesi 33, 20900, Monza, Italy", 
          "id": "http://www.grid.ac/institutes/grid.7563.7", 
          "name": [
            "Research Centre on Public Health (CESP), University of Milan-Bicocca, Via G. Pergolesi 33, 20900, Monza, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cortesi", 
        "givenName": "Paolo Angelo", 
        "id": "sg:person.011005453160.90", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011005453160.90"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Research Centre on Public Health (CESP), University of Milan-Bicocca, Via G. Pergolesi 33, 20900, Monza, Italy", 
          "id": "http://www.grid.ac/institutes/grid.7563.7", 
          "name": [
            "Research Centre on Public Health (CESP), University of Milan-Bicocca, Via G. Pergolesi 33, 20900, Monza, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lafranconi", 
        "givenName": "Alessandra", 
        "id": "sg:person.01122723643.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01122723643.51"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Research Centre on Public Health (CESP), University of Milan-Bicocca, Via G. Pergolesi 33, 20900, Monza, Italy", 
          "id": "http://www.grid.ac/institutes/grid.7563.7", 
          "name": [
            "Research Centre on Public Health (CESP), University of Milan-Bicocca, Via G. Pergolesi 33, 20900, Monza, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Micale", 
        "givenName": "Mariangela", 
        "id": "sg:person.016123245317.50", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016123245317.50"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Research Centre on Public Health (CESP), University of Milan-Bicocca, Via G. Pergolesi 33, 20900, Monza, Italy", 
          "id": "http://www.grid.ac/institutes/grid.7563.7", 
          "name": [
            "Research Centre on Public Health (CESP), University of Milan-Bicocca, Via G. Pergolesi 33, 20900, Monza, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mangano", 
        "givenName": "Sveva", 
        "id": "sg:person.01055073235.86", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01055073235.86"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Research Centre on Public Health (CESP), University of Milan-Bicocca, Via G. Pergolesi 33, 20900, Monza, Italy", 
          "id": "http://www.grid.ac/institutes/grid.7563.7", 
          "name": [
            "Research Centre on Public Health (CESP), University of Milan-Bicocca, Via G. Pergolesi 33, 20900, Monza, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cesana", 
        "givenName": "Giancarlo", 
        "id": "sg:person.01162027016.62", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01162027016.62"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Research Centre on Public Health (CESP), University of Milan-Bicocca, Via G. Pergolesi 33, 20900, Monza, Italy", 
          "id": "http://www.grid.ac/institutes/grid.7563.7", 
          "name": [
            "Research Centre on Public Health (CESP), University of Milan-Bicocca, Via G. Pergolesi 33, 20900, Monza, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mantovani", 
        "givenName": "Lorenzo Giovanni", 
        "id": "sg:person.07442362324.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07442362324.37"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s10198-017-0895-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085441446", 
          "https://doi.org/10.1007/s10198-017-0895-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrrheum.2014.106", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045678566", 
          "https://doi.org/10.1038/nrrheum.2014.106"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10067-017-3636-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085156070", 
          "https://doi.org/10.1007/s10067-017-3636-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10198-011-0335-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037467100", 
          "https://doi.org/10.1007/s10198-011-0335-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40273-015-0350-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016324684", 
          "https://doi.org/10.1007/s40273-015-0350-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00508-016-1111-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052656711", 
          "https://doi.org/10.1007/s00508-016-1111-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12891-016-1102-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033802847", 
          "https://doi.org/10.1186/s12891-016-1102-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40744-016-0042-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018443800", 
          "https://doi.org/10.1007/s40744-016-0042-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00296-016-3514-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005758365", 
          "https://doi.org/10.1007/s00296-016-3514-3"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-02-13", 
    "datePublishedReg": "2018-02-13", 
    "description": "BackgroundPsoriatic arthritis is a long-term inflammatory arthropathy occurring in a subgroup of patients with psoriasis. In addition to irreversible bone erosions, joint destruction, and skin manifestations, psoriatic arthritis is associated with numerous comorbid conditions. Over the last 5\u00a0years, new treatments emerged; the analysis and comparisons of their additional costs and the added benefits have become increasingly important to optimize the limited resources available.MethodsA systematic literature review covering PubMed, EMBASE, and the Cochrane Library was performed from May 2012 to October 2017 focusing on the most recent evidence of costs, benefits, and burden of psoriatic arthritis and its treatments. All economic evaluations assessing the burden of patients with psoriatic arthritis and written in English were eligible for inclusion. We also performed an assessment of the quality of the studies.ResultsOf the 1652 references found in the literature search, nine cost-effectiveness analyses and 12 cost-of-illness studies were included in the current review. Patients with psoriatic arthritis incur substantially higher direct and indirect costs, as compared with patients with psoriasis without arthritis or patients with other inflammatory diseases. The cost of treatment with biologic therapies is the major predictor of the total cost. However, individuals with psoriatic arthritis are also affected by substantial productivity losses and indirect costs. Biologic therapies are generally cost effective vs. conventional therapies (e.g., synthetic drugs) for treating psoriatic arthritis.ConclusionsPsoriatic arthritis is associated with a significant economic burden and biologic therapies contribute significantly to these costs. Biologic therapies are more effective than disease-modifying anti-rheumatic drugs for the symptoms and signs of psoriatic arthritis and for improving quality of life and inhibiting structural radiological damage. Therefore, biologic therapies are cost effective compared with conventional therapies: the increased direct cost associated with biologic drugs is offset by the significant improvement in the efficacy of treatments and in patient management of psoriatic arthritis.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s40273-018-0618-5", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1102812", 
        "issn": [
          "1170-7690", 
          "1179-2027"
        ], 
        "name": "PharmacoEconomics", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "5", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "36"
      }
    ], 
    "keywords": [
      "psoriatic arthritis", 
      "biologic therapy", 
      "conventional therapy", 
      "disease-modifying anti-rheumatic drugs", 
      "anti-rheumatic drugs", 
      "subgroup of patients", 
      "numerous comorbid conditions", 
      "indirect costs", 
      "burden of patients", 
      "efficacy of treatment", 
      "significant economic burden", 
      "quality of life", 
      "cost of treatment", 
      "systematic literature review", 
      "cost-effectiveness analysis", 
      "joint destruction", 
      "bone erosion", 
      "skin manifestations", 
      "comorbid conditions", 
      "radiological damage", 
      "Cochrane Library", 
      "BackgroundPsoriatic arthritis", 
      "inflammatory diseases", 
      "patient management", 
      "arthritis", 
      "illness studies", 
      "economic burden", 
      "patients", 
      "substantial productivity losses", 
      "biologic drugs", 
      "new treatments", 
      "therapy", 
      "literature review", 
      "literature search", 
      "major predictor", 
      "direct costs", 
      "Recent evidence", 
      "psoriasis", 
      "treatment", 
      "current review", 
      "burden", 
      "productivity loss", 
      "drugs", 
      "significant improvement", 
      "economic evaluation", 
      "cost effectiveness", 
      "review", 
      "EMBASE", 
      "ResultsOf", 
      "symptoms", 
      "PubMed", 
      "disease", 
      "efficacy", 
      "manifestations", 
      "subgroups", 
      "predictors", 
      "study", 
      "signs", 
      "total cost", 
      "benefits", 
      "additional cost", 
      "years", 
      "individuals", 
      "damage", 
      "evidence", 
      "assessment", 
      "management", 
      "destruction", 
      "quality", 
      "limited resources", 
      "evaluation", 
      "life", 
      "loss", 
      "analysis", 
      "improvement", 
      "search", 
      "addition", 
      "inclusion", 
      "effectiveness", 
      "comparison", 
      "cost", 
      "English", 
      "conditions", 
      "reference", 
      "library", 
      "erosion", 
      "resources", 
      "incurs", 
      "irreversible bone erosions", 
      "psoriatic arthritis incur", 
      "arthritis incur", 
      "ConclusionsPsoriatic arthritis", 
      "structural radiological damage"
    ], 
    "name": "Cost and Cost Effectiveness of Treatments for Psoriatic Arthritis: A Systematic Literature Review", 
    "pagination": "567-589", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1101005767"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s40273-018-0618-5"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29441473"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s40273-018-0618-5", 
      "https://app.dimensions.ai/details/publication/pub.1101005767"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:42", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_785.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s40273-018-0618-5"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40273-018-0618-5'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40273-018-0618-5'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40273-018-0618-5'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40273-018-0618-5'


 

This table displays all metadata directly associated to this object as RDF triples.

257 TRIPLES      22 PREDICATES      134 URIs      117 LITERALS      13 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s40273-018-0618-5 schema:about N40e5ad922e104a21a42ed720d0384da8
2 N70b46746056f49fe85165f4e539d9a35
3 N74ba847a1da543849dbc0e1303d5c1c8
4 N8aab8167d67f43c9977ea474f60895b3
5 N9df7d9eb5d554006945f350d9aefd266
6 Ne14d016bbf5b4a428eeca83fb6bb4006
7 anzsrc-for:11
8 anzsrc-for:1103
9 schema:author Ne7249ebde50c472284a8f7cd355f99c0
10 schema:citation sg:pub.10.1007/s00296-016-3514-3
11 sg:pub.10.1007/s00508-016-1111-9
12 sg:pub.10.1007/s10067-017-3636-3
13 sg:pub.10.1007/s10198-011-0335-x
14 sg:pub.10.1007/s10198-017-0895-5
15 sg:pub.10.1007/s40273-015-0350-3
16 sg:pub.10.1007/s40744-016-0042-2
17 sg:pub.10.1038/nrrheum.2014.106
18 sg:pub.10.1186/s12891-016-1102-z
19 schema:datePublished 2018-02-13
20 schema:datePublishedReg 2018-02-13
21 schema:description BackgroundPsoriatic arthritis is a long-term inflammatory arthropathy occurring in a subgroup of patients with psoriasis. In addition to irreversible bone erosions, joint destruction, and skin manifestations, psoriatic arthritis is associated with numerous comorbid conditions. Over the last 5 years, new treatments emerged; the analysis and comparisons of their additional costs and the added benefits have become increasingly important to optimize the limited resources available.MethodsA systematic literature review covering PubMed, EMBASE, and the Cochrane Library was performed from May 2012 to October 2017 focusing on the most recent evidence of costs, benefits, and burden of psoriatic arthritis and its treatments. All economic evaluations assessing the burden of patients with psoriatic arthritis and written in English were eligible for inclusion. We also performed an assessment of the quality of the studies.ResultsOf the 1652 references found in the literature search, nine cost-effectiveness analyses and 12 cost-of-illness studies were included in the current review. Patients with psoriatic arthritis incur substantially higher direct and indirect costs, as compared with patients with psoriasis without arthritis or patients with other inflammatory diseases. The cost of treatment with biologic therapies is the major predictor of the total cost. However, individuals with psoriatic arthritis are also affected by substantial productivity losses and indirect costs. Biologic therapies are generally cost effective vs. conventional therapies (e.g., synthetic drugs) for treating psoriatic arthritis.ConclusionsPsoriatic arthritis is associated with a significant economic burden and biologic therapies contribute significantly to these costs. Biologic therapies are more effective than disease-modifying anti-rheumatic drugs for the symptoms and signs of psoriatic arthritis and for improving quality of life and inhibiting structural radiological damage. Therefore, biologic therapies are cost effective compared with conventional therapies: the increased direct cost associated with biologic drugs is offset by the significant improvement in the efficacy of treatments and in patient management of psoriatic arthritis.
22 schema:genre article
23 schema:inLanguage en
24 schema:isAccessibleForFree false
25 schema:isPartOf N23cb2473794345f7a1e3f48b379cb408
26 N924f9796428041b8a89e38bb0a5afb55
27 sg:journal.1102812
28 schema:keywords BackgroundPsoriatic arthritis
29 Cochrane Library
30 ConclusionsPsoriatic arthritis
31 EMBASE
32 English
33 PubMed
34 Recent evidence
35 ResultsOf
36 addition
37 additional cost
38 analysis
39 anti-rheumatic drugs
40 arthritis
41 arthritis incur
42 assessment
43 benefits
44 biologic drugs
45 biologic therapy
46 bone erosion
47 burden
48 burden of patients
49 comorbid conditions
50 comparison
51 conditions
52 conventional therapy
53 cost
54 cost effectiveness
55 cost of treatment
56 cost-effectiveness analysis
57 current review
58 damage
59 destruction
60 direct costs
61 disease
62 disease-modifying anti-rheumatic drugs
63 drugs
64 economic burden
65 economic evaluation
66 effectiveness
67 efficacy
68 efficacy of treatment
69 erosion
70 evaluation
71 evidence
72 illness studies
73 improvement
74 inclusion
75 incurs
76 indirect costs
77 individuals
78 inflammatory diseases
79 irreversible bone erosions
80 joint destruction
81 library
82 life
83 limited resources
84 literature review
85 literature search
86 loss
87 major predictor
88 management
89 manifestations
90 new treatments
91 numerous comorbid conditions
92 patient management
93 patients
94 predictors
95 productivity loss
96 psoriasis
97 psoriatic arthritis
98 psoriatic arthritis incur
99 quality
100 quality of life
101 radiological damage
102 reference
103 resources
104 review
105 search
106 significant economic burden
107 significant improvement
108 signs
109 skin manifestations
110 structural radiological damage
111 study
112 subgroup of patients
113 subgroups
114 substantial productivity losses
115 symptoms
116 systematic literature review
117 therapy
118 total cost
119 treatment
120 years
121 schema:name Cost and Cost Effectiveness of Treatments for Psoriatic Arthritis: A Systematic Literature Review
122 schema:pagination 567-589
123 schema:productId Nbf816e5930c24f409afc7b322fd1c32a
124 Nd020ffe3c1764a3ca1dc5f3ea3f1debf
125 Nf7395e114eae40e6ba35ab610f968376
126 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101005767
127 https://doi.org/10.1007/s40273-018-0618-5
128 schema:sdDatePublished 2021-12-01T19:42
129 schema:sdLicense https://scigraph.springernature.com/explorer/license/
130 schema:sdPublisher Nd470b1bda14543bb82d038b94d165957
131 schema:url https://doi.org/10.1007/s40273-018-0618-5
132 sgo:license sg:explorer/license/
133 sgo:sdDataset articles
134 rdf:type schema:ScholarlyArticle
135 N09e7d2fd731740f893817e86f3eb607d rdf:first sg:person.01122723643.51
136 rdf:rest Na9af970de7e945dcb37bdaab23b3ffb0
137 N23cb2473794345f7a1e3f48b379cb408 schema:volumeNumber 36
138 rdf:type schema:PublicationVolume
139 N40e5ad922e104a21a42ed720d0384da8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Cost-Benefit Analysis
141 rdf:type schema:DefinedTerm
142 N4769cda984fc41aa8acb4c110a179d28 rdf:first sg:person.01055073235.86
143 rdf:rest N6de3dc33d7a54f0d9583c033b0413254
144 N516dbab4b1404bac8a12be48a2ee5e36 rdf:first sg:person.011005453160.90
145 rdf:rest N09e7d2fd731740f893817e86f3eb607d
146 N6de3dc33d7a54f0d9583c033b0413254 rdf:first sg:person.01162027016.62
147 rdf:rest N98d59322df3847e4b38fa2fb78121b84
148 N70b46746056f49fe85165f4e539d9a35 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Cost of Illness
150 rdf:type schema:DefinedTerm
151 N74ba847a1da543849dbc0e1303d5c1c8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Humans
153 rdf:type schema:DefinedTerm
154 N8aab8167d67f43c9977ea474f60895b3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Arthritis, Psoriatic
156 rdf:type schema:DefinedTerm
157 N924f9796428041b8a89e38bb0a5afb55 schema:issueNumber 5
158 rdf:type schema:PublicationIssue
159 N98d59322df3847e4b38fa2fb78121b84 rdf:first sg:person.07442362324.37
160 rdf:rest rdf:nil
161 N9df7d9eb5d554006945f350d9aefd266 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Drug Costs
163 rdf:type schema:DefinedTerm
164 Na9af970de7e945dcb37bdaab23b3ffb0 rdf:first sg:person.016123245317.50
165 rdf:rest N4769cda984fc41aa8acb4c110a179d28
166 Nbf816e5930c24f409afc7b322fd1c32a schema:name pubmed_id
167 schema:value 29441473
168 rdf:type schema:PropertyValue
169 Nd020ffe3c1764a3ca1dc5f3ea3f1debf schema:name dimensions_id
170 schema:value pub.1101005767
171 rdf:type schema:PropertyValue
172 Nd470b1bda14543bb82d038b94d165957 schema:name Springer Nature - SN SciGraph project
173 rdf:type schema:Organization
174 Ne14d016bbf5b4a428eeca83fb6bb4006 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Antirheumatic Agents
176 rdf:type schema:DefinedTerm
177 Ne7249ebde50c472284a8f7cd355f99c0 rdf:first sg:person.01223133176.57
178 rdf:rest N516dbab4b1404bac8a12be48a2ee5e36
179 Nf7395e114eae40e6ba35ab610f968376 schema:name doi
180 schema:value 10.1007/s40273-018-0618-5
181 rdf:type schema:PropertyValue
182 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
183 schema:name Medical and Health Sciences
184 rdf:type schema:DefinedTerm
185 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
186 schema:name Clinical Sciences
187 rdf:type schema:DefinedTerm
188 sg:journal.1102812 schema:issn 1170-7690
189 1179-2027
190 schema:name PharmacoEconomics
191 schema:publisher Springer Nature
192 rdf:type schema:Periodical
193 sg:person.01055073235.86 schema:affiliation grid-institutes:grid.7563.7
194 schema:familyName Mangano
195 schema:givenName Sveva
196 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01055073235.86
197 rdf:type schema:Person
198 sg:person.011005453160.90 schema:affiliation grid-institutes:grid.7563.7
199 schema:familyName Cortesi
200 schema:givenName Paolo Angelo
201 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011005453160.90
202 rdf:type schema:Person
203 sg:person.01122723643.51 schema:affiliation grid-institutes:grid.7563.7
204 schema:familyName Lafranconi
205 schema:givenName Alessandra
206 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01122723643.51
207 rdf:type schema:Person
208 sg:person.01162027016.62 schema:affiliation grid-institutes:grid.7563.7
209 schema:familyName Cesana
210 schema:givenName Giancarlo
211 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01162027016.62
212 rdf:type schema:Person
213 sg:person.01223133176.57 schema:affiliation grid-institutes:grid.7563.7
214 schema:familyName D’Angiolella
215 schema:givenName Lucia Sara
216 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01223133176.57
217 rdf:type schema:Person
218 sg:person.016123245317.50 schema:affiliation grid-institutes:grid.7563.7
219 schema:familyName Micale
220 schema:givenName Mariangela
221 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016123245317.50
222 rdf:type schema:Person
223 sg:person.07442362324.37 schema:affiliation grid-institutes:grid.7563.7
224 schema:familyName Mantovani
225 schema:givenName Lorenzo Giovanni
226 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07442362324.37
227 rdf:type schema:Person
228 sg:pub.10.1007/s00296-016-3514-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005758365
229 https://doi.org/10.1007/s00296-016-3514-3
230 rdf:type schema:CreativeWork
231 sg:pub.10.1007/s00508-016-1111-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052656711
232 https://doi.org/10.1007/s00508-016-1111-9
233 rdf:type schema:CreativeWork
234 sg:pub.10.1007/s10067-017-3636-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085156070
235 https://doi.org/10.1007/s10067-017-3636-3
236 rdf:type schema:CreativeWork
237 sg:pub.10.1007/s10198-011-0335-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1037467100
238 https://doi.org/10.1007/s10198-011-0335-x
239 rdf:type schema:CreativeWork
240 sg:pub.10.1007/s10198-017-0895-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085441446
241 https://doi.org/10.1007/s10198-017-0895-5
242 rdf:type schema:CreativeWork
243 sg:pub.10.1007/s40273-015-0350-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016324684
244 https://doi.org/10.1007/s40273-015-0350-3
245 rdf:type schema:CreativeWork
246 sg:pub.10.1007/s40744-016-0042-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018443800
247 https://doi.org/10.1007/s40744-016-0042-2
248 rdf:type schema:CreativeWork
249 sg:pub.10.1038/nrrheum.2014.106 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045678566
250 https://doi.org/10.1038/nrrheum.2014.106
251 rdf:type schema:CreativeWork
252 sg:pub.10.1186/s12891-016-1102-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1033802847
253 https://doi.org/10.1186/s12891-016-1102-z
254 rdf:type schema:CreativeWork
255 grid-institutes:grid.7563.7 schema:alternateName Research Centre on Public Health (CESP), University of Milan-Bicocca, Via G. Pergolesi 33, 20900, Monza, Italy
256 schema:name Research Centre on Public Health (CESP), University of Milan-Bicocca, Via G. Pergolesi 33, 20900, Monza, Italy
257 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...